Terms: = Brain cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
397 results:
1. Targeting the molecular chaperone CCT2 inhibits GBM progression by influencing kras stability.
Zhao F; Yao Z; Li Y; Zhao W; Sun Y; Yang X; Zhao Z; Huang B; Wang J; Li X; Chen A
Cancer Lett; 2024 May; 590():216844. PubMed ID: 38582394
[TBL] [Abstract] [Full Text] [Related]
2. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
[TBL] [Abstract] [Full Text] [Related]
3. Sotorasib in kras G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
[TBL] [Abstract] [Full Text] [Related]
4. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract] [Full Text] [Related]
5. Application of plasma circulating kras mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract] [Full Text] [Related]
6. HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
Prete AA; Angerilli V; Bergamo F; Vettore V; De Toni C; Intini R; Cerma K; Ricagno G; Cerantola R; Perissinotto E; De Rosa A; Ceccon C; Gasparello J; Denaro L; D'Amico A; Chioffi F; Carcea E; Fassan M; Lonardi S
Br J Cancer; 2024 May; 130(8):1316-1323. PubMed ID: 38347094
[TBL] [Abstract] [Full Text] [Related]
7. [brain Metastasis Following Conversion Surgery for Sigmoid Colon cancer-A Case Report].
Takenoya T; Murai S; Ando H; Nakayama F; Asada Y; Oto I; Yoshikawa T; Nakamura T; Yabe N; Osumi K; Kameyama N
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1522-1524. PubMed ID: 38303328
[TBL] [Abstract] [Full Text] [Related]
8. Mosaic RASopathies concept: different skin lesions, same systemic manifestations?
Morren MA; Fodstad H; Brems H; Bedoni N; Guenova E; Jacot-Guillarmod M; Busiah K; Giuliano F; Gilliet M; Atallah I
J Med Genet; 2024 Apr; 61(5):411-419. PubMed ID: 38290824
[TBL] [Abstract] [Full Text] [Related]
9. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological and molecular characteristics of colorectal adenosquamous carcinoma in an Asian population.
Ye F; Chen M; Zheng X; Huang P; Wang C; Liu H; Xie H; Xiao W; Guo Q; Huang L
BMC Gastroenterol; 2024 Jan; 24(1):36. PubMed ID: 38229035
[TBL] [Abstract] [Full Text] [Related]
11. kras is a molecular determinant of platinum responsiveness in glioblastoma.
Zuchegna C; Leone S; Romano A; Porcellini A; Messina S
BMC Cancer; 2024 Jan; 24(1):77. PubMed ID: 38225605
[TBL] [Abstract] [Full Text] [Related]
12. Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer.
Choi YJ; Choi M; Park J; Park M; Kim MJ; Lee JS; Oh SJ; Lee YJ; Shim WS; Kim JW; Kim MJ; Kim YC; Kang KW
Biomed Pharmacother; 2024 Feb; 171():116124. PubMed ID: 38198957
[TBL] [Abstract] [Full Text] [Related]
13. The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
de Sauvage MA; Torrini C; Nieblas-Bedolla E; Summers EJ; Sullivan E; Zhang BS; Batchelor E; Marion B; Yamazawa E; Markson SC; Wakimoto H; Nayyar N; Brastianos PK
Neuro Oncol; 2024 May; 26(5):889-901. PubMed ID: 38134951
[TBL] [Abstract] [Full Text] [Related]
14. Functional pri-miR-34b/c rs4938723 and kras 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
Vieira IA; Pezzi EH; Bandeira IC; Reis LB; de Araújo Rocha YM; Fernandes BV; Siebert M; Miyamoto KN; Siqueira MB; Achatz MI; Galvão HCR; Garcia FAO; Campacci N; Carraro DM; Formiga MN; Vianna FSL; Palmero EI; Macedo GS; Ashton-Prolla P
Gene; 2024 Mar; 898():148069. PubMed ID: 38070788
[TBL] [Abstract] [Full Text] [Related]
15. Brief report on the efficacy of sotorasib in kras-Mutated NSCLC patients with brain metastases.
Lebouille-Veldman AB; Taros TN; Nawabi NLA; Mekary RA; Peng L; Phillips J
Lung Cancer; 2024 Jan; 187():107425. PubMed ID: 38061200
[TBL] [Abstract] [Full Text] [Related]
16. H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications.
Gestrich C; Grieco K; Lidov HG; Baird LC; Fehnel KP; Yeo KK; Meredith DM; Alexandrescu S
J Neuropathol Exp Neurol; 2023 Dec; 83(1):30-35. PubMed ID: 38037182
[TBL] [Abstract] [Full Text] [Related]
17. Driver gene kras aggravates cancer-associated stroke outcomes.
Yan H; Sasaki T; Gon Y; Nishiyama K; Kanki H; Mochizuki H
Thromb Res; 2024 Jan; 233():55-68. PubMed ID: 38029547
[TBL] [Abstract] [Full Text] [Related]
18. Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs.
Kruithof PD; de Beer YM; Gulikers JL; Stolk LML; Hendriks LEL; Croes S; van Geel RMJM
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Dec; 1231():123918. PubMed ID: 37979367
[TBL] [Abstract] [Full Text] [Related]
19. Glioma genetic profiles associated with electrophysiologic hyperexcitability.
Tobochnik S; Dorotan MKC; Ghosh HS; Lapinskas E; Vogelzang J; Reardon DA; Ligon KL; Bi WL; Smirnakis SM; Lee JW
Neuro Oncol; 2024 Feb; 26(2):323-334. PubMed ID: 37713468
[TBL] [Abstract] [Full Text] [Related]
20. The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung cancer.
Acikgoz Y; Yildirim FU; Esen SA; Ucar G; Ergun Y; Bal O; Dogan M; Uncu D
Am J Clin Oncol; 2023 Dec; 46(12):543-550. PubMed ID: 37700432
[TBL] [Abstract] [Full Text] [Related]
[Next]
